BELLEVUE, Wash.–(BUSINESS WIRE)–Feb. 24, 2004–SCOLR, Inc. (AMEX: DDD - News ) announced today that it entered into definitive agreements with existing and new institutional investors for the purchase of approximately $10.4 million of securities through the sale of 3,206,538 shares of common stock at $3.25 per share. These agreements also involve the acquisition by accredited investors of five-year warrants to purchase an additional 801,635 shares of the Company’s common stock at an exercise price of $4.75. Rodman & Renshaw, Inc. served as placement agent for the transaction.

Daniel O. Wilds, President and CEO of SCOLR, said, “SCOLR will now have the funding to significantly accelerate its oral drug delivery development and to simultaneously pursue multiple routes towards bringing its patented CDT(TM) technology to market in the form of OTC products and prescription drugs.

“While our technology continues to wind its way through the development process, we are pleased to continue to make strides on a corporate level, including our recent listing on the American Stock Exchange,” Wilds added.

Based in Bellevue, Washington, SCOLR, Inc. is a biopharmaceutical company leveraging specialized knowledge, proprietary and patented products and technologies, such as the patented CDT Controlled Delivery Technology platform, to introduce distinctive and novel OTC products, prescription drugs and dietary supplements. SCOLR’s CDT drug delivery platform provides distinctive products with tangible benefits for the consumer and competitive commercial advantages for licensees. Partnerships with pharmaceutical, OTC and natural products industry companies will enable SCOLR to co-develop new products and to add value and protection to existing product franchises. For more information on SCOLR, please call 425.373.0171 or visit http://www.SCOLR.com/ .

The securities were offered to accredited investors in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The securities have not been registered under the Securities Act or any state securities laws and the securities may not be offered or sold absent registration or an applicable exemption from the registration requirement of the Securities Act and applicable state securities laws. In connection with the offering, SCOLR has agreed, subject to certain terms and conditions, to file a registration statement under the Securities Act covering the resale of the shares purchased and shares issuable upon exercise of the warrants. This press release does not and will not constitute an offer to sell or the solicitation of an offer to buy shares or warrants and is being issued under Rule 135c under the Securities Act.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company’s ability to successfully raise capital, to continue to market and provide its products and services and maintain their effectiveness, the continuation of arrangements with the Company’s product development partners and customers, competition, government regulation, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties which are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov . Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
Contact: Bibicoff & Associates, Inc. Terri MacInnis, 818-379-8500 terrimac@pacbell.net

Source: SCOLR, Inc.

BELLEVUE , WA., FEB. 23 , 2004 - SCOLR, Inc. (Amex: DDD) announced today that General Nutrition Centers, Inc. (GNC), the largest specialty retailer of nutritional supplements, is now carrying CDT TM (controlled delivery technology) glucosamine & chondroitin. The 12-hour formulation of 500mg. glucosamine with 400mg. chondroitin tablets is currently available in approximately 2,000 GNC corporate stores.

Glucosamine is used in the treatment of osteoarthritis. According to Frost & Sullivan, national sales of glucosamine increased from estimates of $630 million in 1999 to an estimated projection of $1.58 billion in 2001. SCOLR’s CDT glucosamine & chondroitin improves convenience by extending the release of glucosamine in the gastro-intestinal tract.

“The GNC chain is known for its devotion to helping its customers improve their quality of life and we are pleased that it has selected to offer its customers the convenience and benefits of this distinctive product,” said Daniel O. Wilds, President and CEO of SCOLR. “This is the first of our CDT formulations to be ordered by GNC and we look forward to working with GNC to develop additional products in the future.”

“GNC is the first major chain in the health food industry to recognize the important dosing and manufacturing advantages provided by our patented CDT technologies. Those distinguishing features continue to drive interest in prospective partners who seek to develop additional novel products utilizing our platforms,” Wilds said.

General Nutrition Centers, Inc. (GNC), based in Pittsburgh, PA, is the largest nationwide specialty retailer of vitamin, mineral and herbal supplements, sports nutrition as well as personal care and related products. GNC operates more than 5,000 retail outlets throughout the United States , including over 1,300 domestic franchise locations, and locations in over 30 foreign markets including Canada and Mexico .

Based in Bellevue , Washington , SCOLR , Inc. is a biopharmaceutical company leveraging specialized knowledge, proprietary and patented products and technologies, such as the patented CDT Controlled Delivery Technology platform, to introduce distinctive and novel OTC products, prescription drugs and dietary supplements. SCOLR’s CDT drug delivery platform provides distinctive products with tangible benefits for the consumer and competitive commercial advantages for licensees. P artnerships with pharmaceutical, OTC and natural products industry companies will enable SCOLR to co-develop new products and to add value and protection to existing product franchises. For more information on SCOLR, please call 425.373.0171 or visit

http://www.SCOLR.com/ .

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company’s ability to continue to successfully market and provide its products and services and maintain their effectiveness, the continuation of arrangements with the Company’s product development partners and customers, competition, government regulation, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties which are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov.. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

NEW YORK, Feb. 6 /PRNewswire/ — The American Stock Exchange® (Amex®) today listed the common stock of SCOLR, Inc. under the ticker symbol DDD.

SCOLR, Inc. is a biopharmaceutical company leveraging specialized knowledge, proprietary and patented products and technologies, such as the patented CDT(TM) Controlled Delivery Technology platform, to introduce distinctive and novel OTC products, prescription drugs and dietary supplements. SCOLR’s CDT drug delivery platform provides distinctive products with tangible benefits for the consumer and competitive commercial advantages for licensees. Partnerships with pharmaceutical, OTC and natural products industry companies will enable SCOLR to co-develop new products and to add value and protection to existing product franchises.

“We are pleased to welcome SCOLR to the American Stock Exchange,” said John McGonegal, senior vice president of the Amex Equities Group. “We look forward to working with SCOLR in building increased investor awareness and visibility within the investment community.”

Daniel O. Wilds, President and CEO of SCOLR, said, “With the move from the over-the-counter bulletin board to this major national exchange, the Company has the opportunity to attract a broader investor base and to attract institutional investment interest.”

The specialist in SCOLR, Inc. will be Cohen Specialists L.L.C. For further information on DDD and other Amex-listed companies, please visit www.amex.com .

The American Stock Exchange® (Amex®) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 138 ETFs. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit www.amex.com.

Source: American Stock Exchange